IVVD vs. ADAP, SOPH, PSTX, CADL, JSPR, STRO, BDTX, GLUE, CRBU, and MGTX
Should you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Adaptimmune Therapeutics (ADAP), SOPHiA GENETICS (SOPH), Poseida Therapeutics (PSTX), Candel Therapeutics (CADL), Jasper Therapeutics (JSPR), Sutro Biopharma (STRO), Black Diamond Therapeutics (BDTX), Monte Rosa Therapeutics (GLUE), Caribou Biosciences (CRBU), and MeiraGTx (MGTX). These companies are all part of the "biological products, except diagnostic" industry.
Adaptimmune Therapeutics (NASDAQ:ADAP) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends.
Adaptimmune Therapeutics has higher revenue and earnings than Invivyd. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Comparatively, 17.9% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Adaptimmune Therapeutics has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.
Invivyd has a net margin of 0.00% compared to Invivyd's net margin of -890.13%. Adaptimmune Therapeutics' return on equity of -93.58% beat Invivyd's return on equity.
In the previous week, Invivyd had 1 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 15 mentions for Invivyd and 14 mentions for Adaptimmune Therapeutics. Adaptimmune Therapeutics' average media sentiment score of -0.10 beat Invivyd's score of -0.30 indicating that Invivyd is being referred to more favorably in the news media.
Adaptimmune Therapeutics received 301 more outperform votes than Invivyd when rated by MarketBeat users. However, 63.64% of users gave Invivyd an outperform vote while only 62.47% of users gave Adaptimmune Therapeutics an outperform vote.
Adaptimmune Therapeutics presently has a consensus price target of $2.67, indicating a potential upside of 140.24%. Invivyd has a consensus price target of $11.33, indicating a potential upside of 372.22%. Given Adaptimmune Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Invivyd is more favorable than Adaptimmune Therapeutics.
Summary
Invivyd beats Adaptimmune Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Invivyd News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
